Table 8: Studies of MARS Therapy MARS Study Pathology Nº Patients Type of Study Level of Evidence Study Groups Analysed Variables MARS Controls Mitzner et al..[60] (2000) ACLF 13 RCT (LN) III 18 5 HD 1, 3, 4 Heemann et al..[41] (2002) ACLF 24 RCT (LN) III 12 12 SMT 1, 2, 3, 4, 5 Sen et al..[42] (2004) ACLF 18 RCT (LN) III 9 9 SMT 1, 3, 4, 5 Hassanein et al..[43] (2007) ACLF 70 RCT (HN) II 39 31 SMT 1, 2, 3, 5 Schmidt et al..[56] (2003) ALF 13 RCT (LN) III 8 5 SMT 1, 3, 4 El Banayosy et al.[70] (2004) ALF 27 RCT (LN) III 14 13 HD 1, 3 Montejo et al.[71] (2009) ACLF / ALF 45 Case-control - 19 26 SMT 1, 2, 3, 4, 5 MARS-Prometheus Studies Evenepoel et al.[94] (2006) ACLF 18 Case serie VIII Comparative series 1, 2, 3 Faenza et al.[95] (2008) ACLF 57 Case serie VIII Comparative series 1, 2, 5 Krisper et al.[96] (2005) ACLF 10 RCT (LN) III Crossover 1, 2, 3 Laleman et al.[55] (2006) ACLF 18 RCT (LN) III 6 6 2, 3, 4 Stadlbauer et al.[97] (2006) ACLF 8 RCT (LN) III Crossover 1, 2, 3 Dethloff et al.[59] (2008) ESLD 24 RCT (LN) III 8 8 1, 2, 3, 4